Science Policy This Week: July 6, 2026

The structural inversion of US science governance accelerated on two parallel tracks this week. The Supreme Court's ruling in Trump v. Slaughter stripped for-cause job protections from commissioners at independent executive agencies, while the Office of Management and Budget moved forward with grantmaking reforms that would concentrate federal research funding decisions inside the political-appointee layer. These are not isolated administrative disputes; together they constitute a cascading redesign of the institutional architecture that has buffered federal science from direct executive control since the postwar settlement.

The Removal Power Cascade

The court's determination that the FTC's for-cause removal restriction is unconstitutional — because it infringes on the president's executive authority — places the Nuclear Regulatory Commission, the Federal Communications Commission, and similar bodies on what the Congressional Research Service calls "precarious legal footing." The mechanism is straightforward: the legal precedent that insulated multi-member commissions now erodes with each application. Justice Gorsuch's concurrence names the destination explicitly, urging the court to "finish the journey" and return "legislative and judicial powers" to Congress and the courts. That framing converts a statutory protection question into a structural one — how much delegated authority an independent agency can retain when its leadership is removable at will.

Grantmaking Under Political Gatekeeping

On the funding side, OMB's proposed rule introduces structural friction across the entire federal research pipeline. Senate Appropriations Chair Susan Collins asked OMB Director Russell Vought to extend the comment period by 90 days and remove the pre-issuance review mechanism — the provision that would give political appointees final authority over grant awards — alongside provisions enabling mid-award terminations, removing appeal pathways, and requiring written justifications for payment requests. Senate Democrats, led by Patty Murray, Gary Peters, Chuck Schumer, and Jeff Merkley, went further, calling for outright repeal on the grounds that the rule exceeds OMB's authority. The substantive contest here is not procedural; it is whether scientific merit review or political alignment becomes the binding constraint on who receives federal research dollars.

The Legislative Lag

Congress returns July 13 from recess facing the FY2027 budget and this year's National Defense Authorization Act, with another August recess scheduled before the September 30 shutdown deadline. The House Appropriations Committee has passed two of its twelve bills; the Senate Appropriations Committee has advanced none, reportedly slowed by leadership disputes and the hospitalization of Sen. Mitch McConnell. The asymmetry is the telling structural feature: administrative restructuring through judicial and executive channels is moving faster than legislative countermeasures can be drafted. For anyone tracking science policy, the operational question is no longer whether the architecture is shifting, but how rapidly the downstream feedback — grant timelines, regulatory independence, peer-review insulation — will propagate through the research ecosystem in the next budget cycle.